Back to mobile site

Zymeworks (ZYME) Reiterated at Buy by Stifel After AACR Presentation

April 22, 2026 7:59 AM EDT Send to a Friend
Stifel analyst Stephen Willey reiterated a Buy rating and $47.00 price target on Zymeworks (NASDAQ: ZYME).The analyst commented, "The AACR ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login